Up to 40% of post-stroke patients receive no lipid-lowering therapy despite high recurrence rates, prompting the International Lipid Expert Panel to release aggressive new consensus guidelines.

Published in Progress in Cardiovascular Disease [link here], the guidance aims to standardise inconsistent international recommendations. It targets a broad range of clinicians, including neurologists, cardiologists, and lipidologists, emphasising that ischaemic stroke accounts for two-thirds of all strokes globally, with 40% of high-risk patients experiencing recurrence within five years.

The panel warns that current inadequate diagnosis and management of lipid disorders are driving these recurrence rates. To address this, the panel has established strict new therapeutic targets and biomarkers for risk stratification.

Key Clinical Targets: The New Consensus

The panel recommends that treatment decisions be based on the patient’s estimated 10-year risk of fatal or non-fatal CVD/ASCVD.

Target LDL-C Levels

• High-Risk Patients: <1.8 mmol/L
• Very High-Risk Patients: <1.4 mmol/L
• Performance Goal: At least a 50% reduction from baseline LDL-C for both groups.

Biomarker Cut-offs

• Lp(a): >125 nmol/L indicates high cardiovascular risk; 75–125 nmol/L indicates moderate risk.
• Remnant Cholesterol (RC): 0.6–0.7 mmol/L serves as the cut-off for increased ASCVD risk.

Safety Data: Statins, Bleeds and Dementia

Addressing common clinical hesitations, the authors explicitly challenged the notion that statins increase the risk of intracranial haemorrhage (ICH).

Citing a meta-analysis conducted with the Lipid and Blood Pressure Meta-analysis Collaboration involving 520,000 patients, the panel found no impact of LLT on the risk of haemorrhagic strokes.

Conversely, they said evidence suggested statins significantly reduced morbidity post-ICH.

Statin users demonstrated a lower risk of:

• All-cause mortality: HR 0.38
• Recurrent stroke: HR 0.29

Furthermore, the largest meta-analysis on LLT and dementia found statin therapy was associated with a reduced risk of general dementia (HR 0.86), Alzheimer’s dementia (HR 0.82), and vascular dementia (HR 0.89).

Beyond LDL-C: Testing and Stratification

The authors noted that 50–60% of ischaemic stroke patients present with abnormal lipid levels at baseline. While LDL-C remains the primary metric, the guidance highlights limitations in standard testing.

The panel advises that Serum/plasma apoB may more accurately reflect LDL content in the blood than LDL-C values. Additionally, elevated triglycerides in mild-to-moderate hypertriglyceridaemia should be viewed as a modifiable risk factor for ischaemic stroke.

Treatment Protocol: ‘Lower, Faster, Longer’

The consensus document reinforces the principles of “the earlier, the better” and “the lower, the better” to maximise the reduction of lifetime LDL-C exposure.

While high-intensity statins remain the cornerstone, the panel acknowledges that monotherapy is often insufficient for very high-risk phenotypes.

• Primary Prevention: Patients with low-to-moderate CVD risk should trial lifestyle changes for 3–6 months. If LDL-C remains >2.6 mmol/L, low-dose statins are indicated.
• Secondary Prevention/High Risk: Combination therapy (statin plus ezetimibe) should be considered early.
• Refractory Cases: For patients who are statin-intolerant or fail to achieve the <1.4 mmol/L target, the addition of PCSK9 inhibitors or bempedoic acid is recommended.

The authors stressed that therapeutic persistence is a major hurdle, with adherence dropping sharply 6–12 months post-initiation.

“A strong and transparent doctor–patient relationship is crucial,” the paper concluded.

“Equally important is the patient’s understanding of the disease and therapy goals. Limited knowledge about the need for continuous LDL-C lowering frequently results in doubts about the therapeutic process, especially among asymptomatic patients who do not perceive immediate benefits.”